Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...
Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...
John Tesh reveals how wife Connie Sellecca saved his life during prostate cancer battle. The former TV host credits faith and ...
FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...
Members issued 800 leaflets explaining about ‘Understanding Prostate Cancer’ and the need for early testing particularly if ...
The former 'Entertainment Tonight' co-host revealed in 2015 that he had been diagnosed with a rare form of prostate cancer ...
The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...
John Tesh says he has outlived a terminal cancer prognosis by nearly eight years while continuing treatment for metastatic ...
In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...
Parade on MSN
TV Host John Tesh Is Still Fighting Rare Cancer 10 Years After Being Given 18 Months To Live
He was only given 18 months to live.
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that Part 1 of the ProstACT Global Phase 3 study, the safety and dosimetry lead-in for its therapeutic candidate – TLX591 ...
Roquefort Therapeutics is acquiring exclusive worldwide rights to a clinical-stage tumour inhibitor for £32m in an all-paper ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results